Session » Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics II
-
Abstract Number: 1810
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
-
Abstract Number: 1811
Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
-
Abstract Number: 1812
Adverse Events In Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared To Idiopathic Pulmonary Arterial Hypertension
-
Abstract Number: 1814
The Risk Of Pulmonary Embolism and Deep Venous Thrombosis In Systemic Sclerosis: A Population-Based Cohort Study
-
Abstract Number: 1815
Asymmetric Dimethylarginine Levels In The Early Detection Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension
-
Abstract Number: 2574
Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease
-
Abstract Number: 2575
Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory
-
Abstract Number: 2576
Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
-
Abstract Number: 2577
Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
-
Abstract Number: 2578
Pulmonary Hypertension In Systemic Sclerosis: Clinical Classification and Pulmonary Hypertension Subtypes
-
Abstract Number: 2579
Recommendations For Screening and Detection Of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension
-
Abstract Number: 2580
Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
-
Abstract Number: 2581
Can Changes In NT-Probnp Predict Early Response To Therapy and Prognosis In Systemic Sclerosis Associated Pre-Capillary Pulmonary Hypertension?
-
Abstract Number: 2582
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
-
Abstract Number: 2583
Long-Term Treatment With Endothelin Receptor Antagonist Increases Peripheral Blood Perfusion In Systemic Sclerosis Patients
-
Abstract Number: 2584
Screening and Diagnostic Modalities For Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Systematic Review
-
Abstract Number: 2585
Left Ventricular Dysfunction Reflected By Higher Serum Brain Natriuretic Peptide Accounts For Poorer Prognosis Of Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
-
Abstract Number: 2586
Antinuclear Antibody Negative Systemic Sclerosis Patients Have Less Vasculopathic Disease Manifestations
-
Abstract Number: 2588
Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies
-
Abstract Number: 2589
Scleroderma Patients With Pulmonary Hypertension and Increased Pulmonary Capillary Wedge Pressure In The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
-
Abstract Number: 2590
Laser Speckle Contrast Analysis A New Method To Evaluate Blood Perfusion in Different Skin Areas Of Systemic Sclerosis Patients: Comparison With Laser Doppler Flowmetry
-
Abstract Number: 2591
Scleroderma Renal Crisis and Pulmonary Arterial Hypertension Are Very Rare In The Same Patient
-
Abstract Number: 2592
Clinical Significance Of Endothelial Vasodilator Function Evaluated By Endopat In Patients With Systemic Sclerosis
-
Abstract Number: 2593
The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
-
Abstract Number: 2594
Stabilisation Of Microcirculation In Early Systemic Sclerosis Patients With Diffuse Skin Involvement Following Rituximab Treatment
-
Abstract Number: 2595
Microvascular Abnormalities In Patients With Early Systemic Sclerosis: Less Severe Morphological Changes Compared To Patients With Definite Disease
-
Abstract Number: 2597
Acupressure For The Treatment Of Raynaud’s Phenomenon: A Pilot Randomized Controlled Trial
-
Abstract Number: 2598
Timing and Outcome Of Transition From Primary To Secondary Raynaud’s Phenomenon: A Capillaroscopic Based Study
-
Abstract Number: 2599
Safety and Effectiveness Of Mycophenolate In Systemic Sclerosis: A Systemic Review
-
Abstract Number: 2600
Shear Wave Elastography: A Novel Quantitative Approach For Evaluating Scleroderma Skin
-
Abstract Number: 2601
Modified Rodnan Ultrasound Skin Score: An Ultrasound Skin Scoring Approach In Systemic Sclerosis
-
Abstract Number: 2602
Reduced Frequencies Of Circulating CD8 T Cells In Early Diffuse Cutaneous Systemic Sclerosis Is Associated With Worse Skin Scores
-
Abstract Number: 2603
Are There Differences In Limited Systemic Sclerosis According To Extension Of Skin Involvement?
-
Abstract Number: 2604
Longitudinal Assessment Of Scleroderma Skin By Optical Coherence Tomography: Preliminary Validation Of Sensitivity To Change Over-Time
-
Abstract Number: 2605
Quality Of Life and Psychosocial Aspects In Juvenile Localized Scleroderma
-
Abstract Number: 2607
Evaluation Of The Construct Validity Of The Patient-Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal (GI) Symptoms Measures In Systemic Sclerosis (SSc)
-
Abstract Number: 2608
Coeliac Disease In Scleroderma – Clinical Features, Frequency and Impact Of Screening In Scleroderma
-
Abstract Number: 2609
Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0